Related Experiment Video
Updated: Jul 18, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
Published on: September 4, 2017
Prescreening tools to determine who needs DXA
Elliott N Schwartz1, Dee M Steinberg
1The Northern California Institute for Bone Health, Inc., 3100 Telegraph Avenue, Suite 3000, Oakland, CA 94609, USA. Administrator@betterbones.org
Clinical decision rules (CDRs) help identify low bone mass in women. While most CDRs exceed 80% sensitivity, a lack of consensus on risk factors and testing regions hinders widespread clinical adoption.
Area of Science:
- Osteoporosis research
- Clinical decision support systems
- Women's health
Background:
- Clinical decision rules (CDRs) aim to improve physician practice.
- Several CDRs for identifying low bone mass in women have emerged since the mid-1990s.
- Examples include SCORE, OST (OSTA), OSIRIS, SOFSURF, NOF, ABONE, pBW, ORAI, and weight-only-EPIDOS (WO-E).
Purpose of the Study:
- To review and compare existing CDRs for low bone mass identification.
- To analyze the development and validation cohorts of these CDRs.
- To evaluate the sensitivity and specificity of the available CDRs.
Main Methods:
- Review of literature on CDRs for low bone mass.
- Analysis of development and validation data for each CDR.
- Comparison of sensitivity and specificity metrics.
Main Results:
- All reviewed CDRs demonstrate sensitivities exceeding 80%.
- Specificities for these CDRs are approximately 50%.
- OST is favored for simplicity, SCORE for flexibility, but consensus is lacking on risk factors and DXA regions.
Conclusions:
- A lack of consensus on risk factors and testing regions presents barriers to clinical application of CDRs.
- Widespread adoption requires agreement on a single, globally applicable CDR.
- Standardization is crucial for effectively identifying low bone mass and improving patient care.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019